How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,796 results for

Cardiogenic Shock

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Right Ventricular Dysfunction in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Hemodynamic Analysis of the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial and Registry. (Abstract)

Right Ventricular Dysfunction in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Hemodynamic Analysis of the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial and Registry. The prevalence and significance of right ventricular dysfunction (RVD) in patients with cardiogenic shock due to acute myocardial infarction (AMI-CS) have not been well characterized. We hypothesized that RVD is common in AMI-CS and associated with worse clinical (...) outcomes.We retrospectively analyzed patients with available hemodynamics enrolled in the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial (n = 139) and registry (n = 258) to identify RVD in AMI-CS. RVD was defined by an elevated central venous pressure (CVP), elevated CVP-pulmonary capillary wedge pressure (PCWP) ratio, decreased pulmonary artery pulsatility index, and decreased right ventricular stroke work index. A P value of <.01 was used to infer significance

2019 Journal of cardiac failure Controlled trial quality: uncertain

3. SCAI clinical expert consensus statement on the classification of cardiogenic shock Full Text available with Trip Pro

SCAI clinical expert consensus statement on the classification of cardiogenic shock SCAI clinical expert consensus statement on the classification of cardiogenic shock - Baran - - Catheterization and Cardiovascular Interventions - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. VALVULAR AND STRUCTURAL (...) HEART DISEASES Free Access SCAI clinical expert consensus statement on the classification of cardiogenic shock This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019 Corresponding Author E-mail address: Sentara Heart Hospital, Division of Cardiology, Advanced Heart Failure Center and Eastern Virginia Medical School, Norfolk, Virginia

2019 Society for Cardiovascular Angiography and Interventions

4. Impella CP (Abiomed) for use in adult patients with cardiogenic shock

Impella CP (Abiomed) for use in adult patients with cardiogenic shock Impella CP (Abiomed) for use in adult patients with cardiogenic shock Impella CP (Abiomed) for use in adult patients with cardiogenic shock HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Impella CP (Abiomed) for use in adult patients (...) with cardiogenic shock. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Cardiogenic shock (CS) is an acute life-threatening condition resulting from inadequate blood circulation due to the inability of the heart (most often the left ventricle) to adequately meet systemic tissue demands for oxygen and nutrients. Technology Description: The Impella CP is an intravascular nonpulsatile axial blood pump designed to support the circulatory system during CS, low output

2018 Health Technology Assessment (HTA) Database.

5. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial Full Text available with Trip Pro

Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial The role of intraaortic balloon counterpulsation (IABP) in cardiogenic shock is still a subject of intense debate despite the neutral results of the IABP-SHOCK II trial (Intraaortic Balloon Pump in Cardiogenic Shock II) with subsequent downgrading in international guidelines. So far, randomized data on the impact of IABP on long-term clinical (...) outcomes in patients with cardiogenic shock complicating acute myocardial infarction are lacking. Furthermore, only limited evidence is available on general long-term outcomes of patients with cardiogenic shock treated by contemporary practice.The IABP-SHOCK II trial is a multicenter, randomized, openlabel trial. Between 2009 and 2012, 600 patients with cardiogenic shock complicating acute myocardial infarction undergoing early revascularization were randomized to IABP versus control.Long-term follow

2019 EvidenceUpdates

6. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. (Abstract)

Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. Acute myocardial infarction (AMI) complicated by cardiogenic shock is associated with substantial morbidity and mortality. Although intravascular microaxial left ventricular assist devices (LVADs) provide greater hemodynamic support as compared with intra (...) -aortic balloon pumps (IABPs), little is known about clinical outcomes associated with intravascular microaxial LVAD use in clinical practice.To examine outcomes among patients undergoing percutaneous coronary intervention (PCI) for AMI complicated by cardiogenic shock treated with mechanical circulatory support (MCS) devices.A propensity-matched registry-based retrospective cohort study of patients with AMI complicated by cardiogenic shock undergoing PCI between October 1, 2015, and December 31, 2017

2020 JAMA

7. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses (...) cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association , MD, MSc, FAHA, Chair , MD, MHS, Vice Chair , RN, PhD, FAHA , MD, FAHA , MD, FAHA , MD , MD , MD, FAHA , MD , MD, PhD, FAHA , MD , and PharmD, FAHA MDOn behalf of the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular

2017 American Heart Association

8. Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction

Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction Article Text

2017 Evidence-Based Medicine

9. The 4 Physiologic Etiologies of Shock, and the 3 Etiologies of Cardiogenic Shock

The 4 Physiologic Etiologies of Shock, and the 3 Etiologies of Cardiogenic Shock Dr. Smith's ECG Blog: The 4 Physiologic Etiologies of Shock, and the 3 Etiologies of Cardiogenic Shock Friday, November 30, 2018 A 60-something presented with hypotension, bradycardia, chest pain and back pain. She had a h/o aortic aneurysm, aortic insufficiency, peripheral vascular disease, and hypertension. She had a mechanical aortic valve. She was on anti-hypertensives including atenolol, and on coumadin (...) in aVR: Is this pattern specific for global ischemia due to left main coronary artery disease? J Electrocardiol 2013;46:240-8. Case continued: The chest X-ray was consistent with pulmonary edema, and the ultrasound showed a "plump" inferior vena cava. (This data is all consistent with high right and left sided filling pressures, which is the hallmark of cardiogenic shock -- not obstructive, distributive, or hypovolemic) Aortic dissection was considered (with involvement of the coronary arteries

2019 Dr Smith's ECG Blog

10. Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction Full Text available with Trip Pro

Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction Experimental trials suggest improved outcome by mild therapeutic hypothermia for cardiogenic shock after acute myocardial infarction. The objective of this study was to investigate the hemodynamic effects of mild therapeutic hypothermia in patients with cardiogenic shock complicating acute myocardial infarction.Patients (n=40) with cardiogenic shock undergoing primary percutaneous coronary intervention without classic (...) hypothermia failed to show a substantial beneficial effect on cardiac power index at 24 hours in patients with cardiogenic shock after acute myocardial infarction.URL: https://www.clinicaltrials.gov . Unique identifier: NCT01890317.

2019 EvidenceUpdates

11. Letter by He et al Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". (Abstract)

Letter by He et al Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". 31306071 2019 07 15 1524-4539 140 3 2019 Jul 16 Circulation Circulation Letter by He et al Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". e156-e157 10.1161/CIRCULATIONAHA.118.037036 He Zhiqing Z Department of Cardiology, Shanghai Changzheng Hospital, Second Military Medical

2019 Circulation Controlled trial quality: uncertain

12. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Full Text available with Trip Pro

Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. The DanGer Shock trial test the hypothesis that left ventricular (LV) mechanical circulatory support with Impella CP transvalvular microaxial flow pump improves survival in patients with ST segment elevation acute myocardial infarction complicated by cardiogenic shock (AMICS) compared to conventional guideline-driven treatment. This paper describes the rationale and design of the randomized trial, in addition (...) 10%-30%).The DanGer Shock trial will be the first adequately powered randomized trial to address whether mechanical circulatory LV support with Impella CP can improve survival in AMICS. Baseline characteristics of the first 100 randomized patients indicate a population in profound cardiogenic shock.Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

2019 American Heart Journal Controlled trial quality: uncertain

13. Letter by Bengueddache and Bendjelid Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". (Abstract)

Letter by Bengueddache and Bendjelid Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". 31306062 2019 07 15 1524-4539 140 3 2019 Jul 16 Circulation Circulation Letter by Bengueddache and Bendjelid Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". e154-e155 10.1161/CIRCULATIONAHA.119.040185 Bengueddache Samir S Internal Medicine Division (S.B

2019 Circulation Controlled trial quality: uncertain

14. Letter by Zhu et al Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". (Abstract)

Letter by Zhu et al Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". 31306068 2019 07 15 1524-4539 140 3 2019 Jul 16 Circulation Circulation Letter by Zhu et al Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". e152-e153 10.1161/CIRCULATIONAHA.119.039939 Zhu Jianbing J Department of Cardiology, The First Affiliated Hospital of Nanchang University

2019 Circulation Controlled trial quality: uncertain

15. Cangrelor in Cardiogenic Shock and after Cardiopulmonary Resuscitation: A Global, Multicenter, Matched Pair Analysis with Oral P2Y<sub>12</sub> Inhibition from the IABP-SHOCK II Trial. (Abstract)

Cangrelor in Cardiogenic Shock and after Cardiopulmonary Resuscitation: A Global, Multicenter, Matched Pair Analysis with Oral P2Y12 Inhibition from the IABP-SHOCK II Trial. Cangrelor has a potentially favorable pharmacodynamic profile in cardiogenic shock (CS). We aimed to evaluate the clinical course of CS patients undergoing percutaneous coronary intervention (PCI) treated with cangrelor.We retrospectively identified 136 CS patients treated with cangrelor. Patients were 1:1 (...) matched to CS patients from the IABP-SHOCK II trial not receiving cangrelor by age, sex, cardiac arrest, type of myocardial infarction, culprit lesion, glycoprotein IIb/IIIa inhibitor, and oral P2Y12-receptor inhibitor and followed-up for 12 months. The study cohort consisted of 88 matched pairs. Thirty-day and 12-month mortality was 29.5% and 34.1% in cangrelor-treated patients and 36.4% and 47.1% in control group (P = 0.34 and P = 0.08, respectively). The rate of definite acute stent thrombosis

2019 Resuscitation

16. Response by Fuernau and Thiele to Letters Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". (Abstract)

Response by Fuernau and Thiele to Letters Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". 31306066 2019 07 15 1524-4539 140 3 2019 Jul 16 Circulation Circulation Response by Fuernau and Thiele to Letters Regarding Article, "Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial". e158-e159 10.1161/CIRCULATIONAHA.119.041188 Fuernau Georg G Medical Clinic II (Cardiology

2019 Circulation Controlled trial quality: uncertain

17. Cardiogenic Shock after Nifedipine Administration in a Pregnant Patient: A Case Report and Review of the Literature Full Text available with Trip Pro

Cardiogenic Shock after Nifedipine Administration in a Pregnant Patient: A Case Report and Review of the Literature We present a case of a 21-year-old Caucasian woman at 27 weeks of pregnancy who was admitted to the obstetric department for pre-term labor. She received 10 mg of nifedipine 4 times in 1 h, according to the internal protocol. Shortly after, she brutally deteriorated with pulmonary edema and hypoxemia requiring transfer to the intensive care unit (ICU) for mechanical ventilation (...) . She finally improved and was successfully extubated after undergoing a percutaneous valvuloplasty of the mitral valve. This case illustrates a severe cardiogenic shock after administration of nifedipine for premature labor in a context of unknown rheumatic mitral stenosis. Nifedipine induces a reflex tachycardia that reduces the diastolic period and thereby precipitates pulmonary edema in case of mitral stenosis. This case emphasizes the fact that this drug may be severely harmful and should never

2018 Journal of translational internal medicine

18. Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Full Text available with Trip Pro

Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Heart failure (HF) is an impending complication to myocardial infarction. We hypothesized that the degree of complement activation reflects severity of HF following acute myocardial infarction.The LEAF trial (LEvosimendan in Acute heart Failure following myocardial infarction) evaluating 61 patients developing HF within 48 h after (...) percutaneous coronary intervention-treated ST-elevation myocardial infarction herein underwent a post hoc analysis. Blood samples were drawn from inclusion to Day 5 and at 42 day follow-up, and biomarkers were measured with enzyme immunoassays. Regional myocardial contractility was measured by echocardiography as wall motion score index (WMSI). The cardiogenic shock group (n = 9) was compared with the non-shock group (n = 52). Controls (n = 44) were age-matched and sex-matched healthy individuals. C4bc

2018 ESC heart failure Controlled trial quality: uncertain

19. Clinical outcomes of second-generation limus-eluting stents compared to paclitaxel-eluting stents for acute myocardial infarction with cardiogenic shock. Full Text available with Trip Pro

Clinical outcomes of second-generation limus-eluting stents compared to paclitaxel-eluting stents for acute myocardial infarction with cardiogenic shock. Whether the cardiovascular (CV) outcomes of second-generation limus-eluting stents (LESs) differ from those of paclitaxel-eluting stents (PESs) in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is still unclear.We used the Taiwan National Health Insurance Research Database to analyse data of 516 patients

2019 PLoS ONE

20. Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. Full Text available with Trip Pro

Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. The prevalence of hypoalbuminemia, early changes of plasma albumin (P-Alb) levels, and their effects on mortality in cardiogenic shock are unknown.P-Alb was measured from serial blood samples in 178 patients from a prospective multinational study on cardiogenic shock. The association of hypoalbuminemia with clinical characteristics and course of hospital stay including treatment and procedures was assessed (...) . The primary outcome was all-cause 90-day mortality.Hypoalbuminemia (P-Alb < 34g/L) was very frequent (75%) at baseline in patients with cardiogenic shock. Patients with hypoalbuminemia had higher mortality than patients with normal albumin levels (48% vs. 23%, p = 0.004). Odds ratio for death at 90 days was 2.4 [95% CI 1.5-4.1] per 10 g/L decrease in baseline P-Alb. The association with increased mortality remained independent in regression models adjusted for clinical risk scores developed

2019 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>